Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence

Ricky D. Turgeon; Shelley Zieroth; David Bewick; Chi Ming Chow; Brian Clarke; Simone Cowan; Christopher B. Fordyce; Anne Fournier; Kenneth Gin; Anil Gupta; Sean Hardiman; Simon Jackson; Benny Lau; Howard Leong-Poi; Samer Mansour; Ariane Marelli; Ata Rehman Quraishi; Idan Roifman; Marc Ruel; John Sapp; Gurmeet Singh; Gary Small; Sean Virani; David A. Wood; Andrew Krahn

doi:10.1016/j.cjca.2020.05.033

Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence

Ricky D. Turgeon, Shelley Zieroth, David Bewick, Chi Ming Chow, Brian Clarke, Simone Cowan, Christopher B. Fordyce, Anne Fournier, Kenneth Gin, Anil Gupta, Sean Hardiman, Simon Jackson, Benny Lau, Howard Leong-Poi, Samer Mansour, Ariane Marelli, Ata Rehman Quraishi, Idan Roifman, Marc Ruel, John SappGurmeet Singh, Gary Small, Sean Virani, David A. Wood, Andrew Krahn

Résultat de recherche: Editorial › examen par les pairs

3 Citations (Scopus)

Langue d'origine	English
Pages (de-à)	1180-1182
Nombre de pages	3
Journal	Canadian Journal of Cardiology
Volume	36
Numéro de publication	8
DOI	https://doi.org/10.1016/j.cjca.2020.05.033
Statut de publication	Published - août 2020
Publié à l'externe	Oui

Note bibliographique

Funding Information:
S.Z. has received consulting fees from Novartis and participates in Novartis-sponsored clinical trials. B.C. has participated in consultation and speaking engagements for Novartis Pharmaceuticals, Servier Laboratories, and Boehringer Ingelheim Pharmaceuticals. S.C. was on the National Advisory Board of Novartis (March 2019). G.S. is on the Edwards Lifesciences Advisory Board. SV receives grants and honoraria from Novartis and Servier. The other authors have no conflicts of interest to disclose.

ASJC Scopus Subject Areas

Cardiology and Cardiovascular Medicine

PubMed: MeSH publication types

Editorial

Accès au document

10.1016/j.cjca.2020.05.033

Autres fichiers et liens

Citer

Turgeon, R. D., Zieroth, S., Bewick, D., Chow, C. M., Clarke, B., Cowan, S., Fordyce, C. B., Fournier, A., Gin, K., Gupta, A., Hardiman, S., Jackson, S., Lau, B., Leong-Poi, H., Mansour, S., Marelli, A., Quraishi, A. R., Roifman, I., Ruel, M., ... Krahn, A. (2020). Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence. Canadian Journal of Cardiology, 36(8), 1180-1182. https://doi.org/10.1016/j.cjca.2020.05.033

Turgeon, RD, Zieroth, S, Bewick, D, Chow, CM, Clarke, B, Cowan, S, Fordyce, CB, Fournier, A, Gin, K, Gupta, A, Hardiman, S, Jackson, S, Lau, B, Leong-Poi, H, Mansour, S, Marelli, A, Quraishi, AR, Roifman, I, Ruel, M, Sapp, J, Singh, G, Small, G, Virani, S, Wood, DA & Krahn, A 2020, 'Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence', Canadian Journal of Cardiology, vol. 36, n° 8, pp. 1180-1182. https://doi.org/10.1016/j.cjca.2020.05.033

@article{c17131ccec6e42839e98390a684b2cae,

title = "Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence",

author = "Turgeon, {Ricky D.} and Shelley Zieroth and David Bewick and Chow, {Chi Ming} and Brian Clarke and Simone Cowan and Fordyce, {Christopher B.} and Anne Fournier and Kenneth Gin and Anil Gupta and Sean Hardiman and Simon Jackson and Benny Lau and Howard Leong-Poi and Samer Mansour and Ariane Marelli and Quraishi, {Ata Rehman} and Idan Roifman and Marc Ruel and John Sapp and Gurmeet Singh and Gary Small and Sean Virani and Wood, {David A.} and Andrew Krahn",

note = "Funding Information: S.Z. has received consulting fees from Novartis and participates in Novartis-sponsored clinical trials. B.C. has participated in consultation and speaking engagements for Novartis Pharmaceuticals, Servier Laboratories, and Boehringer Ingelheim Pharmaceuticals. S.C. was on the National Advisory Board of Novartis (March 2019). G.S. is on the Edwards Lifesciences Advisory Board. SV receives grants and honoraria from Novartis and Servier. The other authors have no conflicts of interest to disclose.",

year = "2020",

month = aug,

doi = "10.1016/j.cjca.2020.05.033",

language = "English",

volume = "36",

pages = "1180--1182",

journal = "Canadian Journal of Cardiology",

issn = "0828-282X",

publisher = "Pulsus Group Inc.",

number = "8",

}

TY - JOUR

T1 - Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic

T2 - Early Guidance and Evolving Evidence

AU - Turgeon, Ricky D.

AU - Zieroth, Shelley

AU - Bewick, David

AU - Chow, Chi Ming

AU - Clarke, Brian

AU - Cowan, Simone

AU - Fordyce, Christopher B.

AU - Fournier, Anne

AU - Gin, Kenneth

AU - Gupta, Anil

AU - Hardiman, Sean

AU - Jackson, Simon

AU - Lau, Benny

AU - Leong-Poi, Howard

AU - Mansour, Samer

AU - Marelli, Ariane

AU - Quraishi, Ata Rehman

AU - Roifman, Idan

AU - Ruel, Marc

AU - Sapp, John

AU - Singh, Gurmeet

AU - Small, Gary

AU - Virani, Sean

AU - Wood, David A.

AU - Krahn, Andrew

N1 - Funding Information: S.Z. has received consulting fees from Novartis and participates in Novartis-sponsored clinical trials. B.C. has participated in consultation and speaking engagements for Novartis Pharmaceuticals, Servier Laboratories, and Boehringer Ingelheim Pharmaceuticals. S.C. was on the National Advisory Board of Novartis (March 2019). G.S. is on the Edwards Lifesciences Advisory Board. SV receives grants and honoraria from Novartis and Servier. The other authors have no conflicts of interest to disclose.

PY - 2020/8

Y1 - 2020/8

UR - http://www.scopus.com/inward/record.url?scp=85087983721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087983721&partnerID=8YFLogxK

U2 - 10.1016/j.cjca.2020.05.033

DO - 10.1016/j.cjca.2020.05.033

M3 - Editorial

C2 - 32502522

AN - SCOPUS:85087983721

SN - 0828-282X

VL - 36

SP - 1180

EP - 1182

JO - Canadian Journal of Cardiology

JF - Canadian Journal of Cardiology

IS - 8

ER -